137 related articles for article (PubMed ID: 37879140)
1. Chiral distinction between hydroxychloroquine enantiomers in binding to angiotensin-converting enzyme 2, the forward receptor of SARS-CoV-2.
Aiello F; Balzano F; Uccello Barretta G; D'Acquarica I; Mazzoccanti G; Agranat I
J Pharm Biomed Anal; 2024 Jan; 237():115770. PubMed ID: 37879140
[TBL] [Abstract][Full Text] [Related]
2. Investigating interactions between chloroquine/hydroxychloroquine and their single enantiomers and angiotensin-converting enzyme 2 by a cell membrane chromatography method.
Jia Q; Fu J; Liang P; Wang S; Wang Y; Zhang X; Zhou H; Zhang L; Lv Y; Han S
J Sep Sci; 2022 Jan; 45(2):456-467. PubMed ID: 34729910
[TBL] [Abstract][Full Text] [Related]
3. Cell membrane chromatography for the analysis of the interaction between chloroquine and hydroxychloroquine with ACE2 receptors.
Fu J; Jia Q; Zhou H; Zhang L; Wang S; Liang P; Lv Y; Han S
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jan; 1162():122469. PubMed ID: 33310480
[TBL] [Abstract][Full Text] [Related]
4. A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic.
Tripathy S; Dassarma B; Roy S; Chabalala H; Matsabisa MG
Int J Antimicrob Agents; 2020 Aug; 56(2):106028. PubMed ID: 32450198
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the Modulatory Effect of Hydroxychloroquine on ACE2 Activity: New Insights in relation to COVID-19.
Tichauer JE; Soto D; Andresen M
Biomed Res Int; 2021; 2021():6614000. PubMed ID: 34337036
[TBL] [Abstract][Full Text] [Related]
6. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
7. Development of a chiral HPLC method for the separation and quantification of hydroxychloroquine enantiomers.
Xiong X; Wang K; Tang T; Fang J; Chen Y
Sci Rep; 2021 Apr; 11(1):8017. PubMed ID: 33850241
[TBL] [Abstract][Full Text] [Related]
8. Chloroquine and Hydroxychloroquine Interact Differently with ACE2 Domains Reported to Bind with the Coronavirus Spike Protein: Mediation by ACE2 Polymorphism.
Badraoui R; Adnan M; Bardakci F; Alreshidi MM
Molecules; 2021 Jan; 26(3):. PubMed ID: 33525415
[TBL] [Abstract][Full Text] [Related]
9. Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine.
Choudhury M; Dhanabalan AK; Goswami N
J Cell Biochem; 2022 Feb; 123(2):347-358. PubMed ID: 34741481
[TBL] [Abstract][Full Text] [Related]
10. Hydroxychloroquine blocks SARS-CoV-2 entry into the endocytic pathway in mammalian cell culture.
Yuan Z; Pavel MA; Wang H; Kwachukwu JC; Mediouni S; Jablonski JA; Nettles KW; Reddy CB; Valente ST; Hansen SB
Commun Biol; 2022 Sep; 5(1):958. PubMed ID: 36104427
[TBL] [Abstract][Full Text] [Related]
11. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
[TBL] [Abstract][Full Text] [Related]
12. Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story.
Gasmi A; Peana M; Noor S; Lysiuk R; Menzel A; Gasmi Benahmed A; Bjørklund G
Appl Microbiol Biotechnol; 2021 Feb; 105(4):1333-1343. PubMed ID: 33515285
[TBL] [Abstract][Full Text] [Related]
13. Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection.
Infante M; Ricordi C; Alejandro R; Caprio M; Fabbri A
Expert Rev Anti Infect Ther; 2021 Jan; 19(1):5-16. PubMed ID: 32693652
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.
de Barros CM; Almeida CAF; Pereira B; Costa KCM; Pinheiro FA; Maia LDB; Trindade CM; Garcia RCT; Torres LH; Diwan S; Boralli VB
Pain Physician; 2020 Aug; 23(4S):S351-S366. PubMed ID: 32942793
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
[TBL] [Abstract][Full Text] [Related]
16. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
[TBL] [Abstract][Full Text] [Related]
17. Hydroxychloroquine treatment on SARS-CoV-2 receptor ACE2, TMPRSS2 and NRP1 expression in human primary pterygium and conjunctival cells.
Yao Y; Ma D; Xu Y; Yuan XL; Liang JJ; Chen SL; Jhanji V; Ng TK
Exp Eye Res; 2022 Jan; 214():108864. PubMed ID: 34826419
[TBL] [Abstract][Full Text] [Related]
18. Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection.
Klimke A; Hefner G; Will B; Voss U
Med Hypotheses; 2020 Sep; 142():109783. PubMed ID: 32402766
[TBL] [Abstract][Full Text] [Related]
19. Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19.
Lei ZN; Wu ZX; Dong S; Yang DH; Zhang L; Ke Z; Zou C; Chen ZS
Pharmacol Ther; 2020 Dec; 216():107672. PubMed ID: 32910933
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings.
Kalra RS; Tomar D; Meena AS; Kandimalla R
Pathogens; 2020 Jul; 9(7):. PubMed ID: 32645974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
